COMMUNIQUÉS West-GlobeNewswire

Bilan semestriel du Contrat de Liquidité de DBV Technologies avec ODDO BHF
06/07/2026
Informations Réglementées Châtillon, France, le 6 juillet (22 h 30 CET) 2026 Bilan semestriel du Contrat de Liquidité de DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : [...]
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
06/07/2026
PDUFA Target Action Date Set for April 24, 2027 CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the [...]
Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
06/07/2026
Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical [...]
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/07/2026
WALTHAM, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer [...]
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/07/2026
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Alberta Cancer Foundation invests $35-million to power cancer clinical trials for Albertans
06/07/2026
Historic funding over the next five years strengthens Alberta’s newly launched 10-Year Cancer Care Strategy CALGARY, Alberta, July 06, 2026 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is investing $35-million to [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 27 - 2026
06/07/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 30 juin au 3 juillet 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
06/07/2026
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non- [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026
06/07/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 30th June to 03rd July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
06/07/2026
Company announcement No. 31 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 27, 2026) Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL [...]
Catheter Precision, Inc. Announces Issuance of Two Key Patents
06/07/2026
New Intellectual Property Covers VIVO Technology and Cardionomix Heart Failure Technology FORT MILL, SC, July 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision Inc., (VTAK: NYSE/American), a US based medical device [...]
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
06/07/2026
TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]
La recommandation du CMUH fait passer le TECVAYLI®▼ (teclistamab) de Johnson & Johnson, associé au daratumumab, au rang de traitement conventionnel potentiel pour le myélome multiple récidivant ou réfractaire
06/07/2026
Recommandation étayée par des données inédites issues d’une étude de Phase 3, démontrant que TECVAYLI ® , en association avec le daratumumab, a permis d’obtenir des améliorations statistiquement significatives en termes [...]
Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026
06/07/2026
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook [...]
NewGen’s Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million
06/07/2026
Midpoint equity value for planned UAE cell sorting entity highlights significant growth runway in high-infertility, medical-tourism hotspot Senior Strategic Advisor Nadeem Malik, former CEO of Genetics and IVF Institute [...]
LIXTE Completes Corporate Name Change to NOMAD Power Solutions, Inc.; To Begin Trading Under New Nasdaq Symbol NMAD
06/07/2026
-- New Corporate Identity Reflects Strategic Transition into AI Energy Infrastructure Equipment & Services Sector Following Acquisition of NOMAD Transportable Power Systems -- BOCA RATON, Fla., July 06, 2026 (GLOBE [...]
Amplia Announces Changes to Board’s Leadership Roles
06/07/2026
Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan. Dr Warwick [...]
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
06/07/2026
Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that [...]
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
06/07/2026
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals Telehealth offers patients the convenience of an integrated online [...]

Pages